{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:17:11Z","timestamp":1794608231602,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In cirrhotic patients, portal hypertension (PHT) deteriorates survival, yet treatment options are limited. A major contributor to increased intrahepatic vasoconstriction in PHT is dysfunctional nitric-oxide signaling. Soluble guanylate cyclase (sGC) is the receptor of nitric-oxide and can be stimulated by riociguat. Riociguat is approved for pulmonary hypertension but has not been studied in liver cirrhosis. In this study we assessed the effects of riociguat on PHT and liver fibrosis in cholestatic (bile duct ligation, BDL) and toxic (carbon-tetrachloride, CCl4) rat models. In cirrhotic livers sGC expression was upregulated. In BDL rats, riociguat reduced liver fibrosis and decreased portal pressure without affecting systemic hemodynamics. In an early BDL disease stage, riociguat decreased bile duct proliferation, improved sinusoidal vascular dysfunction and inhibited angiogenesis. In advanced BDL riociguat exhibited anti-inflammatory effects. In CCl4 rats the beneficial effects of riociguat treatment were less pronounced and confined to an early disease stage. Similarly, in patients with cholestatic cirrhosis and PHT nitrates (that induce sGC activity) decreased portal pressure more effectively than in patients with non-cholestatic etiology. We also found an improvement of transaminases in patients with pulmonary hypertension receiving riociguat. Our findings support the clinical development of sGC stimulators in patients with cirrhotic PHT.<\/jats:p>","DOI":"10.1038\/s41598-018-27656-y","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T14:22:59Z","timestamp":1528899779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-8076","authenticated-orcid":false,"given":"Philipp","family":"Schwabl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Brusilovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Supper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-1148","authenticated-orcid":false,"given":"Philipp","family":"K\u00f6nigshofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Daniela","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Stift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Oberhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aschauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Gnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Erhard","family":"Uschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Rohr-Udilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Karl","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"27656_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis, R. & Baveno, V. I. F. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of hepatology 63, 743\u2013752, https:\/\/doi.org\/10.1016\/j.jhep.2015.05.022 (2015).","journal-title":"Journal of hepatology"},{"key":"27656_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","volume":"63","author":"C Villanueva","year":"2016","unstructured":"Villanueva, C. et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology 63, 197\u2013206, https:\/\/doi.org\/10.1002\/hep.28264 (2016).","journal-title":"Hepatology"},{"key":"27656_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","volume":"62","author":"T Reiberger","year":"2013","unstructured":"Reiberger, T. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62, 1634\u20131641, https:\/\/doi.org\/10.1136\/gutjnl-2012-304038 (2013).","journal-title":"Gut"},{"key":"27656_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/liv.12795","volume":"35","author":"P Schwabl","year":"2015","unstructured":"Schwabl, P. et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver international: official journal of the International Association for the Study of the Liver 35, 2121\u20132128, https:\/\/doi.org\/10.1111\/liv.12795 (2015).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"27656_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","volume":"66","author":"T Reiberger","year":"2017","unstructured":"Reiberger, T. & Mandorfer, M. Beta adrenergic blockade and decompensated cirrhosis. Journal of hepatology 66, 849\u2013859, https:\/\/doi.org\/10.1016\/j.jhep.2016.11.001 (2017).","journal-title":"Journal of hepatology"},{"key":"27656_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa003223","volume":"345","author":"C Villanueva","year":"2001","unstructured":"Villanueva, C. et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. The New England journal of medicine 345, 647\u2013655, https:\/\/doi.org\/10.1056\/NEJMoa003223 (2001).","journal-title":"The New England journal of medicine"},{"key":"27656_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/gastro\/gox011","volume":"5","author":"P Schwabl","year":"2017","unstructured":"Schwabl, P. & Laleman, W. Novel treatment options for portal hypertension. Gastroenterology report 5, 90\u2013103, https:\/\/doi.org\/10.1093\/gastro\/gox011 (2017).","journal-title":"Gastroenterology report"},{"key":"27656_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","volume":"60","author":"P Schwabl","year":"2014","unstructured":"Schwabl, P. et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Journal of hepatology 60, 1135\u20131142, https:\/\/doi.org\/10.1016\/j.jhep.2014.01.025 (2014).","journal-title":"Journal of hepatology"},{"key":"27656_CR9","doi-asserted-by":"publisher","unstructured":"Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of hepatology, https:\/\/doi.org\/10.1016\/j.jhep.2016.12.005 (2016).","DOI":"10.1016\/j.jhep.2016.12.005"},{"key":"27656_CR10","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.27343","volume":"61","author":"M Fernandez","year":"2015","unstructured":"Fernandez, M. Molecular pathophysiology of portal hypertension. Hepatology 61, 1406\u20131415, https:\/\/doi.org\/10.1002\/hep.27343 (2015).","journal-title":"Hepatology"},{"key":"27656_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/jhep.2002.31432","volume":"35","author":"R Wiest","year":"2002","unstructured":"Wiest, R. & Groszmann, R. J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35, 478\u2013491, https:\/\/doi.org\/10.1053\/jhep.2002.31432 (2002).","journal-title":"Hepatology"},{"key":"27656_CR12","doi-asserted-by":"publisher","first-page":"14753","DOI":"10.1073\/pnas.96.26.14753","volume":"96","author":"Y Zhao","year":"1999","unstructured":"Zhao, Y., Brandish, P. E., Ballou, D. P. & Marletta, M. A. A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proceedings of the National Academy of Sciences of the United States of America 96, 14753\u201314758 (1999).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"27656_CR13","doi-asserted-by":"publisher","first-page":"9416","DOI":"10.1021\/bi800682k","volume":"47","author":"L Capece","year":"2008","unstructured":"Capece, L., Estrin, D. A. & Marti, M. A. Dynamical characterization of the heme NO oxygen binding (HNOX) domain. Insight into soluble guanylate cyclase allosteric transition. Biochemistry 47, 9416\u20139427, https:\/\/doi.org\/10.1021\/bi800682k (2008).","journal-title":"Biochemistry"},{"key":"27656_CR14","doi-asserted-by":"publisher","first-page":"43053","DOI":"10.1074\/jbc.M112.393892","volume":"287","author":"NB Fernhoff","year":"2012","unstructured":"Fernhoff, N. B., Derbyshire, E. R., Underbakke, E. S. & Marletta, M. A. Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide. The Journal of biological chemistry 287, 43053\u201343062, https:\/\/doi.org\/10.1074\/jbc.M112.393892 (2012).","journal-title":"The Journal of biological chemistry"},{"key":"27656_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cmdc.200900014","volume":"4","author":"J Mittendorf","year":"2009","unstructured":"Mittendorf, J. et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4, 853\u2013865, https:\/\/doi.org\/10.1002\/cmdc.200900014 (2009).","journal-title":"ChemMedChem"},{"key":"27656_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrd2038","volume":"5","author":"OV Evgenov","year":"2006","unstructured":"Evgenov, O. V. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature reviews. Drug discovery 5, 755\u2013768, https:\/\/doi.org\/10.1038\/nrd2038 (2006).","journal-title":"Nature reviews. Drug discovery"},{"key":"27656_CR17","unstructured":"Ignarro, L. J. Nitric Oxide: Biology and Pathobiology. 2 edn, 305 (Academic Press - Elsevier Inc., 2010; 305)."},{"key":"27656_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1161\/ATVBAHA.108.165043","volume":"28","author":"Z Zhou","year":"2008","unstructured":"Zhou, Z. et al. Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Arteriosclerosis, thrombosis, and vascular biology 28, 1803\u20131810, https:\/\/doi.org\/10.1161\/ATVBAHA.108.165043 (2008).","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"27656_CR19","doi-asserted-by":"publisher","first-page":"12312","DOI":"10.1073\/pnas.0703944104","volume":"104","author":"N Sayed","year":"2007","unstructured":"Sayed, N., Baskaran, P., Ma, X., van den Akker, F. & Beuve, A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proceedings of the National Academy of Sciences of the United States of America 104, 12312\u201312317, https:\/\/doi.org\/10.1073\/pnas.0703944104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Suppl 1","key":"27656_CR20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"P Sandner","year":"2017","unstructured":"Sandner, P. & Stasch, J. P. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Respiratory medicine 122(Suppl 1), S1\u2013S9, https:\/\/doi.org\/10.1016\/j.rmed.2016.08.022 (2017).","journal-title":"Respiratory medicine"},{"key":"27656_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. The New England journal of medicine 369, 319\u2013329, https:\/\/doi.org\/10.1056\/NEJMoa1209657 (2013).","journal-title":"The New England journal of medicine"},{"key":"27656_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hypertension. The New England journal of medicine 369, 330\u2013340, https:\/\/doi.org\/10.1056\/NEJMoa1209655 (2013).","journal-title":"The New England journal of medicine"},{"key":"27656_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-0031-1296471","volume":"58","author":"A Knorr","year":"2008","unstructured":"Knorr, A. et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittel-Forschung 58, 71\u201380, https:\/\/doi.org\/10.1055\/s-0031-1296471 (2008).","journal-title":"Arzneimittel-Forschung"},{"key":"27656_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1053\/j.gastro.2011.12.017","volume":"142","author":"G Xie","year":"2012","unstructured":"Xie, G. et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 142, 918\u2013927 e916, https:\/\/doi.org\/10.1053\/j.gastro.2011.12.017 (2012).","journal-title":"Gastroenterology"},{"key":"27656_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2036.2006.02735.x","volume":"23","author":"P Deibert","year":"2006","unstructured":"Deibert, P. et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver\u2013results of a pilot study. Alimentary pharmacology & therapeutics 23, 121\u2013128, https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02735.x (2006).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"27656_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","volume":"47","author":"W Kreisel","year":"2015","unstructured":"Kreisel, W. et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 47, 144\u2013150, https:\/\/doi.org\/10.1016\/j.dld.2014.10.018 (2015).","journal-title":"Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"key":"27656_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1055\/s-0031-1296453","volume":"59","author":"SM Choi","year":"2009","unstructured":"Choi, S. M. et al. Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension. Arzneimittel-Forschung 59, 641\u2013646, https:\/\/doi.org\/10.1055\/s-0031-1296453 (2009).","journal-title":"Arzneimittel-Forschung"},{"key":"27656_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/CS20090601","volume":"119","author":"KC Lee","year":"2010","unstructured":"Lee, K. C. et al. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clinical science 119, 45\u201355, https:\/\/doi.org\/10.1042\/CS20090601 (2010).","journal-title":"Clinical science"},{"key":"27656_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0168-8278(99)80228-1","volume":"31","author":"M Van de Casteele","year":"1999","unstructured":"Van de Casteele, M., Hosli, M., Sagesser, H. & Reichen, J. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. Journal of hepatology 31, 300\u2013305 (1999).","journal-title":"Journal of hepatology"},{"key":"27656_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1478-3231.2008.01664.x","volume":"28","author":"E Biecker","year":"2008","unstructured":"Biecker, E. et al. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver international: official journal of the International Association for the Study of the Liver 28, 331\u2013338, https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01664.x (2008).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"27656_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1478-3231.2004.00892.x","volume":"24","author":"I Colle","year":"2004","unstructured":"Colle, I., De Vriese, A. S., Van Vlierberghe, H., Lameire, N. H. & DeVos, M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver international: official journal of the International Association for the Study of the Liver 24, 63\u201368, https:\/\/doi.org\/10.1111\/j.1478-3231.2004.00892.x (2004).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"27656_CR32","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/hep.22285","volume":"47","author":"DA Langer","year":"2008","unstructured":"Langer, D. A. et al. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology 47, 1983\u20131993, https:\/\/doi.org\/10.1002\/hep.22285 (2008).","journal-title":"Hepatology"},{"key":"27656_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/labinvest.2009.104","volume":"90","author":"LM Lopez-Sanchez","year":"2010","unstructured":"Lopez-Sanchez, L. M. et al. Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis. Laboratory investigation; a journal of technical methods and pathology 90, 116\u2013127, https:\/\/doi.org\/10.1038\/labinvest.2009.104 (2010).","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"27656_CR34","doi-asserted-by":"publisher","first-page":"G535","DOI":"10.1152\/ajpgi.00297.2005","volume":"290","author":"RE Perri","year":"2006","unstructured":"Perri, R. E. et al. Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. American journal of physiology. Gastrointestinal and liver physiology 290, G535\u2013542, https:\/\/doi.org\/10.1152\/ajpgi.00297.2005 (2006).","journal-title":"American journal of physiology. Gastrointestinal and liver physiology"},{"key":"27656_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1006\/jsre.1998.5382","volume":"79","author":"WS Scott","year":"1998","unstructured":"Scott, W. S. & Nakayama, D. K. Sustained nitric oxide exposure decreases soluble guanylate cyclase mRNA and enzyme activity in pulmonary artery smooth muscle. The Journal of surgical research 79, 66\u201370, https:\/\/doi.org\/10.1006\/jsre.1998.5382 (1998).","journal-title":"The Journal of surgical research"},{"issue":"Suppl 1","key":"27656_CR36","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/sj.ijir.3901207","volume":"16","author":"CS Lin","year":"2004","unstructured":"Lin, C. S. Tissue expression, distribution, and regulation of PDE5. International journal of impotence research 16(Suppl 1), S8\u2013S10, https:\/\/doi.org\/10.1038\/sj.ijir.3901207 (2004).","journal-title":"International journal of impotence research"},{"key":"27656_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0167-4889(01)00086-6","volume":"1539","author":"D Giordano","year":"2001","unstructured":"Giordano, D., De Stefano, M. E., Citro, G., Modica, A. & Giorgi, M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochimica et biophysica acta 1539, 16\u201327 (2001).","journal-title":"Biochimica et biophysica acta"},{"key":"27656_CR38","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1681\/ASN.V12112209","volume":"12","author":"F Theilig","year":"2001","unstructured":"Theilig, F. et al. Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. Journal of the American Society of Nephrology: JASN 12, 2209\u20132220 (2001).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"27656_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cardiores.2007.06.002","volume":"76","author":"S Nimmegeers","year":"2007","unstructured":"Nimmegeers, S., Sips, P., Buys, E., Brouckaert, P. & Van de Voorde, J. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation. Cardiovascular research 76, 149\u2013159, https:\/\/doi.org\/10.1016\/j.cardiores.2007.06.002 (2007).","journal-title":"Cardiovascular research"},{"key":"27656_CR40","unstructured":"Dao, V. et al. A non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease. BMC Pharmacology and Toxicology 18(Suppl 1):64, 32(A66) (2017)."},{"key":"27656_CR41","doi-asserted-by":"publisher","first-page":"L369","DOI":"10.1152\/ajplung.2001.281.2.L369","volume":"281","author":"D Li","year":"2001","unstructured":"Li, D., Laubach, V. E. & Johns, R. A. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. American journal of physiology. Lung cellular and molecular physiology 281, L369\u2013376 (2001).","journal-title":"American journal of physiology. Lung cellular and molecular physiology"},{"key":"27656_CR42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/hep.510240432","volume":"24","author":"M Niederberger","year":"1996","unstructured":"Niederberger, M. et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 24, 947\u2013951, https:\/\/doi.org\/10.1002\/hep.510240432 (1996).","journal-title":"Hepatology"},{"key":"27656_CR43","doi-asserted-by":"publisher","first-page":"21722","DOI":"10.1074\/jbc.M000753200","volume":"275","author":"V Sauzeau","year":"2000","unstructured":"Sauzeau, V. et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. The Journal of biological chemistry 275, 21722\u201321729, https:\/\/doi.org\/10.1074\/jbc.M000753200 (2000).","journal-title":"The Journal of biological chemistry"},{"key":"27656_CR44","doi-asserted-by":"publisher","first-page":"20246","DOI":"10.1074\/jbc.271.34.20246","volume":"271","author":"M Amano","year":"1996","unstructured":"Amano, M. et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). The Journal of biological chemistry 271, 20246\u201320249 (1996).","journal-title":"The Journal of biological chemistry"},{"key":"27656_CR45","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/gut.2005.081059","volume":"55","author":"Q Zhou","year":"2006","unstructured":"Zhou, Q. et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55, 1296\u20131305, https:\/\/doi.org\/10.1136\/gut.2005.081059 (2006).","journal-title":"Gut"},{"key":"27656_CR46","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","volume":"57","author":"S Klein","year":"2012","unstructured":"Klein, S. et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. Journal of hepatology 57, 1220\u20131227, https:\/\/doi.org\/10.1016\/j.jhep.2012.07.033 (2012).","journal-title":"Journal of hepatology"},{"key":"27656_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/HYPERTENSIONAHA.108.114207","volume":"52","author":"M Sakurada","year":"2008","unstructured":"Sakurada, M., Shichiri, M., Imamura, M., Azuma, H. & Hirata, Y. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells. Hypertension 52, 903\u2013909, https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.114207 (2008).","journal-title":"Hypertension"},{"key":"27656_CR48","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0006-291X(03)01507-9","volume":"308","author":"CL Smith","year":"2003","unstructured":"Smith, C. L. et al. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochemical and biophysical research communications 308, 984\u2013989 (2003).","journal-title":"Biochemical and biophysical research communications"},{"key":"27656_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","volume":"51","author":"T Reiberger","year":"2009","unstructured":"Reiberger, T. et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of hepatology 51, 865\u2013873, https:\/\/doi.org\/10.1016\/j.jhep.2009.06.024 (2009).","journal-title":"Journal of hepatology"},{"key":"27656_CR50","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0304264101","volume":"101","author":"A Ahluwalia","year":"2004","unstructured":"Ahluwalia, A. et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proceedings of the National Academy of Sciences of the United States of America 101, 1386\u20131391, https:\/\/doi.org\/10.1073\/pnas.0304264101 (2004).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"27656_CR51","doi-asserted-by":"publisher","first-page":"G747","DOI":"10.1152\/ajpgi.00323.2015","volume":"310","author":"DZ Wang","year":"2016","unstructured":"Wang, D. Z., Jones, A. W., Wang, W. Z., Wang, M. & Korthuis, R. J. Soluble guanylate cyclase activation during ischemic injury in mice protects against postischemic inflammation at the mitochondrial level. American journal of physiology. Gastrointestinal and liver physiology 310, G747\u2013756, https:\/\/doi.org\/10.1152\/ajpgi.00323.2015 (2016).","journal-title":"American journal of physiology. Gastrointestinal and liver physiology"},{"key":"27656_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/apt.13844","volume":"45","author":"P Schwabl","year":"2017","unstructured":"Schwabl, P. et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease. Alimentary pharmacology & therapeutics 45, 139\u2013149, https:\/\/doi.org\/10.1111\/apt.13844 (2017).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"27656_CR53","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/hep.510280623","volume":"28","author":"M Trauner","year":"1998","unstructured":"Trauner, M., Mennone, A., Gigliozzi, A., Fraioli, F. & Boyer, J. L. Nitric oxide and guanosine 3\u2032,5\u2032-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. Hepatology 28, 1621\u20131628, https:\/\/doi.org\/10.1002\/hep.510280623 (1998).","journal-title":"Hepatology"},{"key":"27656_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bpg.2011.02.001","volume":"25","author":"M Penz-Osterreicher","year":"2011","unstructured":"Penz-Osterreicher, M., Osterreicher, C. H. & Trauner, M. Fibrosis in autoimmune and cholestatic liver disease. Best practice & research. Clinical gastroenterology 25, 245\u2013258, https:\/\/doi.org\/10.1016\/j.bpg.2011.02.001 (2011).","journal-title":"Clinical gastroenterology"},{"key":"27656_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/labinvest.3700030","volume":"84","author":"G Ramadori","year":"2004","unstructured":"Ramadori, G. & Saile, B. Portal tract fibrogenesis in the liver. Laboratory investigation; a journal of technical methods and pathology 84, 153\u2013159, https:\/\/doi.org\/10.1038\/labinvest.3700030 (2004).","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"27656_CR56","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1086\/685647","volume":"6","author":"S Saleh","year":"2016","unstructured":"Saleh, S., Becker, C., Frey, R. & Muck, W. Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment. Pulmonary circulation 6, S75\u201385, https:\/\/doi.org\/10.1086\/685647 (2016).","journal-title":"Pulmonary circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27656-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:31:35Z","timestamp":1671604295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27656-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27656"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27656-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"9 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.Sc. has received speaker fees from Roche and Boehringer Ingelheim, and travel support from Roche, Boehringer Ingelheim and Gilead. D.Bo. has received fees and research grants from Bayer, AOP Orphan, United Therapeutics, Actelion, Pfizer and Novartis. M.P.R. has received advisory board fees from Abbott, Bayer, BMS, Boehringer-Ingelheim, Gilead, MSD, Roche; has received grants from Abbott, Bayer, Gilead, MSD and Roche. M.T. has received advisory board fees from Falk, Phenex, Albireo, Novartis, Gilead, MSD, Intercept and BMS; has received speaker fees from Falk, Gilead, Roche and MSD; has received grants from Intercept, Albireo, Falk, MSD and Takeda. T.R. received travel support from Roche, MSD, Boehringer Ingelheim and Gilead; received honoraria for lectures from Roche, Boehringer-Ingelheim and MSD, and received research support from Boehringer-Ingelheim and Abbvie. K.B., P.Su., D.Ba., P.K., F.R., H.H., C.D.F., J.S., G.O., S.A., T.G., A.P., F.E.U., J.T., N.R.U. and B.K.P. have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9372"}}